Document is current
Any future updates will be listed below
-
Authors
Lledó-Delgado, Ana
Preston-Hurlburt, Paula
Higdon, Lauren
Hu, Alex
James, Eddie https://orcid.org/0000-0002-7217-5729
Lim, Noha
Long, S. Alice https://orcid.org/0000-0002-0281-1240
McNamara, James
Nguyen, Hai
Serti, Elisavet https://orcid.org/0000-0003-4129-0254
Sumida, Tomokazu S. https://orcid.org/0000-0002-9806-2642
Herold, Kevan C. https://orcid.org/0000-0003-1534-6613
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (DK057846, AI66387, UM1AI109565)
Colton Foundation
- License Information
-
More Information
Article History
Received: 13 June 2023
Accepted: 20 May 2025
First Online: 30 May 2025
Change Date: 23 June 2025
Change Type: Update
Change Details: In this article the affiliation details for Hai Nguyen were incorrectly given as ‘Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA’ but should have been ‘Center for Translational Immunology, Benaroya Research Institute at VirginiaMason, Seattle,WA, USA’. The original article has been corrected.
Competing interests
: S.A.L. and K.C.H. are listed as a co-inventors for a patent on the use of teplizumab for delay of Type 1 diabetes. K.C.H. has consulted for Sanofi Pharma. The other authors declare no competing interests
